Part 4: Metastatic prostate cancer and HRR defects

Part 5: BRCA 1/2 mutations and prostate cancer

Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021

Lineage plasticity in lung cancer- biological and therapeutic implications

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)

Cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer

OncoAlert and ecancer weekly round up for July 1- July 10, 2021

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia

Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC

FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types

ASCO 2021: Precision and molecular reporting for prostate cancer